To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
OncLive
An OncLive® State of the Science Summit™ on multiple myeloma, chaired by Jeffrey Zonder, M.D., hematologist and medical oncologist, leader of the Multiple Myeloma and Amyloidosis Multidisciplinary Team (MDT) and member of the Hematology Oncology MDT at Karmanos, led to many great discussions on the latest developments in the care for multiple myeloma patients. Dr. Zonder was accompanied on the panel by Abhinav Deol, M.D., Andrew Kin, M.D., and Craig Cole, M.D., all members of the Multiple Myeloma and Amyloidosis MDT. Here is a summary of their discussion about teclistamab, the first bispecific antibody to be approved by the Food and Drug Administration for relapsed/refractory multiple myeloma patients.
Read the article here.